Ireland
--:--IST
Latest
Clinical Trials in Italy / NCT03983512
Active, not recruiting Not applicable

PULSTA Transcatheter Pulmonary Valve Pre-Approval Study

NCT03983512 · tracked via the Priya Life Science Italy tracker
Sponsor
Taewoong Medical Co., Ltd
Phase
Not applicable
Started
2019-10-07
Last updated
2026-04-13

Condition(s) studied

Heart DiseasesPulmonary Valve RegurgitationPulmonary Valve StenosisTetralogy of Fallot

Investigational drug(s) / intervention(s)

PULSTA TPV System

PULSTA TPV System: PULSTA transcatheter pulmonary valve replacement.

Study summary

The purpose of the study is to evaluate the safety and effectiveness of the PULSTA Transcatheter Pulmonary Valve (TPV) System for the treatment of congenital or acquired pulmonary valve stenosis and/or regurgitation who require pulmonary valve replacement.

Eligibility

Sex
ALL
Min age
10 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Body weight greater than or equal to 30 kilograms * Pulmonary regurgitation moderate or severe pulmonary regurgitation or pulmonary valve stenosis with mean gradient \>35mmHg by echocardiography * Main pulmonary artery trunk of ≥16 mm and ≤30 mm * Patients willing to provide written informed consent and comply with follow-up evaluations. Exclusion Criteria: * Females of child-bearing potential who are unable to take adequate contraceptive precautions, are known to be pregnant, or are currently breastfeeding an infant up until 6 months after TPV implantation * Pre-existing mechanical valve in pulmonary position or require concomitant repair of other cardiac valves * Obstruction of the central veins to be approached for the TPV implantation * Coronary artery compression confirmed by angiography * A known severe allergy to Nickel * A known hypersensitivity to any anticoagulation therapy, contrast agent or a hemorrhagic disease * Suspected active infectious disease (e.g. endocarditis, meningitis) * Life expectancy of less than 6 months

Primary outcome measure(s)

Trial sites (11)

FacilityCityRegionStatus
Deutsches Herzzentrum Munchen München München
Policlinico San Donato Milan San Donato Milanese
Utrecht University Wilhelmina Utrecht Utrecht
Erasmus Medical Center Rotterdam Wytemaweg
Seoul National University Hospital Seoul Daehak-ro Jongno-gu
Sejong General Hospital Bucheon-si Hohyun-ro, Sosa-gu
Severance Hospital Seoul Yonsei-ro, Seodaemun-gu
Gregorio Marañon hospital Madrid Madrid
University Hospital La Paz Madrid Madrid
Koc University Hospital Istanbul Topkapı, Zetinburnu/İstanbul
Siyami Ersek Hospital Istanbul Üsküdar/İstanbul

More Taewoong Medical Co., Ltd. trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03983512 on ClinicalTrials.gov ↗ ← All trials in Italy